After Hours
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. After-hours trades for Pacira BioSciences Inc. (PCRX) shows that investor sentiment remained same, with the stock’s consolidated last price remained same to $43.38. The Pacira BioSciences Inc. has recorded 8,094 volume in the after hours trading session.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
Stocks Info
PCRX belongs to the Healthcare sector of the NASDAQ while operating in the Drug Manufacturers – Specialty & Generic industry. At the end of the last regular session, the stock closed at $43.38 and fluctuated between $44.42 as its day high and $42.12 as its day low. The current market capitalization of Pacira BioSciences Inc. is $2.03B. A total of 0.77 million shares were traded on the day, compared to an average of 576.19K shares.
Insider Activity
Investors also take into account insider trades in predicting how the stock will perform in the future. During the recent three months, PCRX has seen 0 BUY and 2 SELL insider trades, representing the acquisition of 0 and the disposition of 704 shares. Over the last 12 months, there were 38 BUYs and 50 SELLs from insiders. Insiders purchased 282,073 shares during that period but sold 167,009.
In the most recent transaction, MOLLOY ANTHONY sold 546 shares of PCRX for 38.31 per share on Jan 05. After the transaction, the Chief Lgl & Compliance Officer now owns 19,450 company shares. In a previous transaction on Jan 04, MOLLOY ANTHONY sold 158 shares at 39.09 per share. PCRX shares that Chief Lgl & Compliance Officer owns now total 19,996.
Among the insiders who sold shares, REINHARDT MAX disposed of 1,380 shares on Oct 07 at a per-share price of $58.00. This resulted in the President, Rest of World holding 31,378 shares of PCRX after the transaction. In another insider transaction, WINSTON ROY sold 476 shares at $55.70 per share on Aug 03. Company shares held by the Chief Medical Officer now total 44,992.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. According to analysts who have offered 12-month price targets for PCRX in the last 3 months, the mean price target is $63.80 with high estimates of $90.00 and low estimates of $50.00. In terms of 52-week highs and lows, PCRX has a high of $82.16 and a low of $35.35.
As of this writing, PCRX has an earnings estimate of $0.87 per share for the current quarter. EPS was calculated based on a consensus of 9 estimates, with a high estimate of $1.03 per share and a lower estimate of $0.7. The company reported an EPS of $0.51 in the last quarter, which was -40.00% lower than expectations of $0.85.
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information.
Analysts Opinion
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 10 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for PCRX is Hold with a score of 4.44. A total of 7 analysts rated the stock as Buy while 1 rated it as Overweight while 2 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.
